Background
Background and rationale
Objectives
-
Aspirin at 81 mg/day or 325 mg/day reduces urinary prostaglandin metabolites (PGE-M), a biomarker of prostaglandin tone, to levels associated with low risk of colorectal neoplasia
-
Aspirin at 81 mg/day or 325 mg/day reduces plasma macrophage inhibitory cytokine-1 (MIC-1), an inflammatory biomarker
-
Aspirin at 81 mg/day or 325 mg/day impairs binding of transcription factor 7-like 2 (TCF7L2)/T-cell factor 4 (TCF4) at the 8q24 CRC risk locus in colonic epithelium, particularly among individuals with the 8q24 CRC susceptibility allele
-
Aspirin at 81 mg/day or 325 mg/day lowers expression of Wnt signaling genes (CTNNB1, AXIN-2 and MYC) and hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) in colonic epithelium
-
Aspirin at 81 mg/day or 325 mg/day is associated with less neoplastic nanomorphological cellular signatures from brushings of normal colorectal mucosa
-
Aspirin at 81 mg/day or 325 mg/day is associated with an increase in oral and gut microbial diversity, function, and genomic richness and inhibits microbial pathways associated with CRC
Methods/design
Trial design
Participants, interventions and outcomes
Study setting
Eligibility criteria
Inclusion criteria | Exclusion criteria |
---|---|
• Adenoma removed during qualifying endoscopy (as confirmed by pathology) • Not currently taking aspirin (any dose) within the last 6 months • Age 18–80 years • Able to swallow pills • Ability to understand and the willingness to sign a written Informed Consent Document • ECOG performance status ≤2 • (Karnofsky Index score ≥60%) | • Any adenoma that was not completely removed during previous colonoscopy • Known diagnosis of familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) • Diagnosis of inflammatory bowel disease, liver or kidney disease, or bleeding diathesis • Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestinal, colon, pancreatic), or any diagnosis of other cancers (with the exception of non-melanomatous neoplasia of skin) in which there has been any active treatment within the last 3 years • Use of any nonaspirin, nonsteroidal anti-inflammatory drug (NSAID) at any dose at least 3 times/week during the 2 months prior to randomization • History of aspirin intolerance, bleeding diathesis, peptic ulcer or gastrointestinal bleed, endoscopic complications, or contraindication to colonoscopy • History of allergic reactions attributed to compounds of similar chemical or biologic composition to aspirin • Taking any anticoagulant agent (e.g., warfarin) or antiplatelet agent (e.g., clopidogrel) • Receiving any other investigational agents • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements • Pregnant or breastfeeding |
Interventions
Outcomes
-
Plasma MIC-1, an inflammatory biomarker
-
TCF7L2/TCF4 binding at the 8q24 CRC risk locus in colonic epithelium
-
Wnt signaling proteins (i.e., β-catenin, AXIN-2 and MYC) and HPGD gene expression as measured by ribonucleic acid (RNA)-sequencing (RNA-seq) of sorted colonic epithelial cell populations
-
Spectral biomarkers of colorectal carcinogenesis from cytology brushings
-
Bacterial populations and products associated with CRC in saliva and stool